great scott lab back futur
thesi updat far perfect
good one could ask thing consid lab
volum adjust ton nois appear on-trend
margin soft preview clariti dtc
genom weak like miss like hurt capac
built big holiday season thank
correct covanc strong across board
substanti omx main highlight initi
guid fine better fear manag didnt
back expect modest growth capit alloc
also remain activ debt pay consist
repurchas thu share still well recent high
favor setup continu see risk
reward favor bias continu view mani
issu plagu lab tempor discuss note
yday turn expect rel valuat re-expand
histor level given reiter o/p rate
rais pt
modest downtick dx oi cvd omx expect
robust forecast come
assum repurchas price tick tax rate estim
higher pt move equat ep
line w/ year averag turn peak level
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
includ neg impact divestur bp fx
dx revenu flat due pama
pama reduc revenu consist lower direct medicar
reimburs mm indirect impact reimburs primarili
medicar relat plan mm
organ volum flat slightli
covanc revenu growth
includ neg impact bp fx
revenu growth rate fy guidanc rang primarili due time
neg impact fx
expect modest growth driven covanc launchpad capit deploy partial off-set
pama reduc ep
dx busi given pama manag care contract
guidanc assum yoy increas cybersecur expenditur mm per share
expect compar adjust ep impli lower total year ep
vs prior year primarili due time covanc revenu growth ramp
launchpad save year impact acquisit divestur well impact
calendar
invest mm global facil
expect use share repo
flat yoy
neg impact sever non-operational item
implement pama advers weather
fewer revenue day one extra payrol day fx
bp pama
bp weather
bp calendar
bp divestur
bp pama
partial off-set test mix
 volum bp organ declin bp
launchpad initi deliv mm net save next year
incur mm one-tim implement cost
expect realiz roughli total save year
book bill
track deliv mm net save covanc year launchpad initi
end mm cost synergi integr chiltern end
repurchas mm stock paid mm debt invest mm acquisit
new repurchas plan bn stock
complet re-contract price pleas term
rfp busi strong across board
see strength biotech pharma
data solut side covanc lead gain book
built guidanc busi consist year
saw improv decemb hospit referr busi stabil start grow
encourag perform januari respect manag care contract accuraci intern
estim point
pleas price manag care renew
psc walgreen store within year
store end
store consist grow
np favor
valuat methodolog base mix discount cash flow analysi rel valuat multipl
downsid risk potenti pama relat price cut bleed commerci price ultim lead
neg margin cycl recent vertic integr hc servic organ lead increas price pressur given
heighten focu unit cost challeng associ integr small outreach lab deal could depress return
invest capit prove distract effort off-set pama cut increas cost save could yield servic challeng
ultim depress core organ volum poor perform major clinic trial could harm cvd reput lead
signific shift cro relat market share signific down-tick biotech relat fund could lead materi
growth downshift earli phase demand harm profit
laboratori corp america
articl articl
time dissemin februari
analyst elizabeth anderson suzi yoon ross muken primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani
issuer part research analyst compens directli relat specif recommend view
research report
